Skip to main content

Table 2 Relationship between clinical outcome and multi-locus genotypes

From: Relationship between Trypanosoma brucei rhodesiense genetic diversity and clinical spectrum among sleeping sickness patients in Uganda

Characteristic

Frequency

Associated MLGs

Severity of neurological response

 Mild (13–15)

19 (82.6%)

1,2,3,4,5,6,7,8,9,10,12,13,14,15,16,17

 Moderate (9–12)

3

11,13,14

 Severe (≤ 8)

1

4

Disease duration (months)

 < 1

14 (63.6%)

4,5,9,12,13,14,16,17

 1–3

7

1,2,3,6,8,10,11

 > 3

1

4

Clinical presentation

 Fever

  Yes

24 (100%)

1,2,3,4,5,6,7,8,9,10,11,12,13,14,16,17

  No

0

 

 Headache

  Yes

22 (91.7%)

1,2,3,4,5,7,8,9,10,11,12,13,14,15

  No

2

9,17

 Hepatomegaly

  Yes

2 (8.3%)

4,5

  No

22

1,2,3,4,6,7,8,9,10,11,12,13,14,15,16,17

 Lymphadenopathy

  Yes

8 (33.3%)

2,4,9,10,13,14,15

  No

16

1,3,4,5,6,7,8,9,11,12,13,14,15,16,17

 Splenomegaly

  Yes

6 (25%)

4,5,9,13,14,16

  No

18

1,2,3,4,6,7,8,9,10,11,12,13,14,15,17

 Edema

  Yes

4 (16.7%)

4,13,16

  No

20

1,2,3,4,5,5,6,7,8,9,10,11,12,13,14,15,17

 Somnolence

  Yes

9 (37.5%)

1,2,3,5,6,8,9,10,12

  No

15

2,4,7,11,13,14,15,16,17

 Gait abnormalities

  Yes

6 (25%)

1,4,13,9,11

  No

18

2,3,4,5,6,7,8,9,10,12,13,14,15,16,17

 Tremors

  Yes

2 (8.3%)

11,15

  No

22

1,2,3,4,5,6,7,8,9,10,12,13,14,15,16,17

 Urinary incontinence

  Yes

2 (8.3%)

4,11

  No

22

1,2,3,4,5,6,7,8,9,10, 12,13,14,15,16,17

 Cranioneuropathy

  Yes

3 (15%)

14,15

  No

20

1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16

  1. Multi-locus genotypes indicated in italics were present in those with and without the clinical sign or across groups